CAS: 66264-77-5; 4-[1-Hydroxy-2-[4-(4-Methoxyphenyl)Butan-2-Ylamino]Ethyl]-2-Methylsulfinylphenol

该化合物是属于磺酰胺类的化学化合物,其特点是其磺酰胺组,通常与各种生物活动有关;Sulfinalol因其在药用化学中的潜在用途而闻名,特别是作为一种抗血压剂,因为它能够影响血管平稳肌肉放松;该化合物在水和有机溶剂中表现出中等的溶解性,这可能影响其生物利用率和药用动力;其分子结构包括有助于其再活动以及与生物目标相互作用的功能组;此外,Sulfinalol可能进行代谢转化,导致各种可产生不同药理效应的代谢物;同许多磺酰胺衍生物一样,必须考虑其安全特征,包括敏感个人的潜在过敏反应;

结构式图片

MSDS等安全信息

    上下游产品

    4-羟基-Alpha-[[[3-(4-甲氧基苯基)-1-甲基丙基]氨基]甲基]-3-(甲硫基)苄醇 4-Hydroxy-α-({[3-(4-Methoxyphenyl)-1-Methylpropyl]Amino}Methyl)-3-(Methylthio)Benzyl Alcohol 66264-72-0

    合成工艺路线路线简述

      📜4-羟基-Alpha-[[[3-(4-甲氧基苯基)-1-甲基丙基]氨基]甲基]-3-(甲硫基)苄醇 反应生成 硫氧洛尔
      参考文献:Philion,Richard E.
      标题:Philion,Richard E.

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-2008287407-A1
      优先权日:2003-12-10
      标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
      发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
      权利人:NITROMED INC
      摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

      专利号:US-7708989-B2
      优先权日:1999-10-29
      标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
      发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
      权利人:NITROMED INC
      摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

      专利号:US-7384976-B2
      优先权日:2001-05-02
      标 题:Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
      发明人:GARVEY DAVID S
      权利人:NITROMED INC
      摘要:The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.

      专利号:US-2008214827-A1
      优先权日:2004-02-03
      标 题:Synthesis of Cyanoimino-Benzoimidazoles
      发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
      权利人:EURO CELTIQUE SA
      摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

      专利号:US-7235237-B2
      优先权日:1999-10-29
      标 题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
      发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
      权利人:NITROMED INC
      摘要:The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      合成参考文献


      参考文献:10.1016/s0090-9556(25)06558-4
      摘要:Benziger DP, Fritz A, Edelson J. Metabolism and disposition of sulfinalol in laboratory animals. Drug Metabolism and Disposition. 1981 Nov;9(6):493–8. doi: 10.1016/s0090-9556(25)06558-4.
      摘要:Park GB, Koss RF, DeFelice AF, O'Neil SK, Edelson J. The pharmacokinetics and pharmacodynamics of sulfinalol hydrochloride in dogs after intravenous administration. Arch Int Pharmacodyn Ther. 1982 Sep;259(1):4–13.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知